StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the stock.

Separately, JMP Securities reiterated a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Down 5.5 %

DBVT stock opened at $4.99 on Friday. The stock’s 50 day moving average is $4.48 and its two-hundred day moving average is $3.83. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $8.32. The company has a market capitalization of $102.64 million, a PE ratio of -1.11 and a beta of 0.71.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent reporting period. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.